Tenet (THC) (BIG) (BSX) (UVV) (HMA) (HCA) Biggest NYSE Losers

Tenet Healthcare Co. (NYSE:THC), Big Lots, Inc. (NYSE:BIG), Boston Scientific (NYSE:BSX), Universal Corporation (NYSE:UVV), Health Management Associates (NYSE:HMA) and HCA Holdings Inc. (NYSE:HCA) were the biggest losers on the NYSE, Friday.

Tenet Healthcare Co. (THC) ended down 9.40 percent, closing at $4.24. They traded in a range of $4.05 to $4.78. A total of 18,379,389 shares changed hands.

Big Lots, Inc. (BIG) ended down 8.94 percent, closing at $36.18. They traded in a range of $35.65 to $37.43. A total of 5,601,230 shares changed hands.

Boston Scientific (BSX) ended down 7.63 percent, closing at $5.45. They traded in a range of $5.32 to $6.00. A total of 41,537,040 shares changed hands.

Universal Corporation (UVV) ended down 7.59 percent, closing at $42.25. They traded in a range of $41.53 to $45.24. A total of 1,408,545 shares changed hands.

Health Management Associates (HMA) ended down 7.52 percent, closing at $7.50. They traded in a range of $7.35 to $8.24. A total of 7,907,598 shares changed hands.

HCA Holdings Inc. (HCA) ended down 7.28 percent, closing at $22.43. They traded in a range of $21.55 to $24.47. A total of 7,734,969 shares changed hands.

Boston Scientific (BSX) Ratings Reiterations

Boston Scientific (NYSE: BSX) had ratings on them reiterated by numerous analysts.

Deutsche Bank (NYSE:DB) reiterated its "Hold" rating on Boston Scientific (BSX).

Piper Jaffray (NYSE:PJC) reiterated its "Neutral" rating on Boston Scientific. They have a price target of $7.00 on the company.

Oppenheimer reiterated its "Market Perform" rating on Boston Scientific.

Morgan Stanley (NYSE:MS) reiterated its "Equal Weight" rating on Boston Scientific.

Brean Murray reiterated its "Hold" rating on Boston Scientific.

Bank of America (NYSE:BAC) reiterated its "Neutral" rating on Boston Scientific. They have a price target of $8.50 on the company.

Jefferies (NYSE:JEF) reiterated its "Hold" rating on Boston Scientific. They have a price target of $6.50 on the company.

Goldman Sachs (NYSE:GS) reiterated its "Neutral" rating on Boston Scientific. They have a price target of $5.80 on the company.

Boston Scientific (BSX) Ratings, Price Targets

Boston Scientific (BSX) ratings and price targets.

Deutsche Bank (NYSE:DB) reiterated its “Hold” rating on Boston Scientific (BSX).

Piper Jaffray (NYSE:PJC) lowered its price target on Boston Scientific (BSX) to $6.00.

Piper Jaffray reiterated its “Neutral” on Boston Scientific (BSX). They have a price target of $7.00 on the company.

Oppenheimer reiterated its “Market Perform” on Boston Scientific (BSX).

Morgan Stanley (NYSE:MS) reiterated its “Equal Weight” on Boston Scientific (BSX).

Brean Murray reiterated its “Hold” rating on Boston Scientific (BSX).

Randgold (GOLD) (ABT) (UTHR) (BHE) (SANM) (BSX) Downgraded

Randgold Resources Ltd. (NASDAQ: GOLD), Abbott Laboratories (NYSE: ABT), United Therapeutics (NASDAQ: UTHR), Benchmark Electronics, Inc. (NYSE: BHE), Sanmina-SCI Co. (NASDAQ: SANM) and Boston Scientific (NYSE: BSX) downgraded by analysts.

Randgold Resources Ltd. (GOLD) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating.

Abbott Laboratories (ABT) was downgraded by Morgan Keegan from an “Outperform” rating to a “Market Perform” rating. They have a price target of $57.00 on the company, down from $60.00.

United Therapeutics (UTHR) was downgraded by JPMorgan Chase & Co. (NYSE:JPM) from an “Overweight” rating to a “Neutral” rating.

Benchmark Electronics, Inc. (BHE) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating. They have a price target of $13.00 on the company, down from $20.00.

Sanmina-SCI Co. (SANM) was downgraded by RBC Capital from a “Sector Perform” rating to an “Underperform” rating. They have a price target $5.00 on the company, down from $12.00.

Boston Scientific (BSX) was downgraded by Morgan Keegan from an “Outperform” rating to a “Market Perform” rating. They have a price target of $7.00 on the company, down from $8.00.

Limelight (LLNW) (WAT) (ARRS) (BSX) (SEAC) (CHKP) Get New Coverage

Limelight Networks (NASDAQ: LLNW), Waters Corporation (NYSE: WAT), Arris Group, Inc. (NASDAQ: ARRS), Boston Scientific (NYSE: BSX), SeaChange (NASDAQ: SEAC) and Check Point Software (NASDAQ: CHKP) get new analyst coverage.

Madison Williams initiated coverage on Waters Corporation (NYSE: WAT) is now covered by analysts at . The analysts placed a “neutral” rating on the company.

Kaufman Brothers initiated coverage on Arris Group, Inc. (ARRS). They placed a “Buy” rating and a price target of $12.00 on the company.

Jefferies (NYSE:JEF) initiated coverage on Limelight Networks (LLNW). They placed a “Buy” rating and a price target of $3.75 on the company.

Mizuho initiated coverage on Boston Scientific (BSX). They placed an “Outperform” rating on the company.

Kaufman Brothers initiated coverage on SeaChange (SEAC). They placed a “Hold” rating and a price target of $9.00 on the company.

Jefferies initiated coverage on Check Point Software (CHKP). They placed a “Buy” rating and a price target of $66.00 on the company.

Noble (NBL) (BSX) (AGCO) (COKE) (KEX) (MMI) Price Targets Changed

Noble Energy (NYSE: NBL), Boston Scientific (NYSE: BSX), AGCO Corp. (NASDAQ: AGCO), Coca-Cola Bottling Co. Consolidated (NASDAQ: COKE), Kirby Co. (NYSE: KEX) and Motorola Mobility (NYSE: MMI) price targets adjusted by analysts.

Boston Scientific (NYSE: BSX) had its price target lowered by Citigroup (NYSE:C) to $7.30.

AGCO Corp. (AGCO) had its price target cut by RBC Capital from $64.00 to $62.00. They have a “Sector Perform” rating on the company.

Coca-Cola Bottling Co. Consolidated (COKE) had its price target raised by JPMorgan Chase & Co. (NYSE:JPM) to $36.00.

Kirby Co. (KEX) had its price target raised by RBC Capital from $65.00 to $74.00. They have an “Outperform” rating on the company.

Motorola Mobility (MMI) had its price target lowered by UBS AG (NYSE:UBS) to $31.00. They have a “Buy” rating on the company.

Noble Energy (NBL) had its price target raised by UBS AG (NYSE:UBS) from $110.00 to $113.00. They have a “Buy” rating on the company.

NYSE's (HRZ) (USNA) (ETM) (TMM) (BSX) Biggest Losers

Horizon Lines, Inc. (NYSE:HRZ), USANA Health Sciences, Inc. (NYSE:USNA), Entercom Communications (NYSE:ETM), Grupo TMM, S.A.B. (NYSE:TMM) and Boston Scientific Corporation (NYSE:BSX) were all trading down over 9 percent on the NYSE today.

Horizon Lines, Inc. (HRZ) was trading at $1.50, dropping $0.32, or 17.59 percent, as of 2:21 PM EDT.

USANA Health Sciences, Inc. (USNA) was trading at $32.40, falling $5.31, or 14.09 percent.

Entercom Communications (ETM) was trading at $9.05, plunging $1.15, or 11.27 percent.

Grupo TMM, S.A.B. (TMM) was trading at $2.07, declining $0.23, or 10.00 percent.

Boston Scientific Corporation (BSX) was trading at $6.95, down $0.76, or 9.86 percent.

St. Jude Medical (STJ) Earnings Drop Ends Streak

Shares of St. Jude Medical (NYSE:STJ) are trading strong even after a disappointing quarter where net income for St. Jude Medical, Inc. was down to $233.4 million, or 71 cents a share, vs. $238.6 million, or 73 cents a share last year in the same quarter, a decline of 2.2 percent.

Revenue jumped for the quarter, rising 9 percent to $1.38 billion.

St. Jude Medical missed on the average analyst estimate of 78 cents a share. Estimates ranged from 77 cents a share to 80 cents a share.

St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks said, “During the first quarter, we continued to make good progress in developing the new growth drivers we need to return to double-digit sales growth on a sustainable basis. Our gross margin has strengthened, we have continued to invest in research and development at an elevated rate, and our sales and earnings growth outlook have both improved. We are off to a good start making 2011 another very successful year for St. Jude Medical.”

Major competitors of St. Jude Medical include Medtronic, Inc. (NYSE:MDT), Boston Scientific Corporation (NYSE:BSX), Intuitive Surgical, Inc. (NASDAQ:ISRG), Johnson & Johnson (NYSE:JNJ), and Edwards Lifesciences Corp. (NYSE:EW).

St. Jude Medical was trading at $52.75, gaining $1.75, or 3.43 percent, as of 1:22 PM EDT.

Boston Scientific (BSX) Stent Confirmed Effective

In a clinical trial a heart stent manufactured by Boston Scientific Corp. (NYSE:BSX) has been proven to be as effective as one already on the market, which was developed by Abbott Laboratories Inc (NYSE:ABT), a major competitor of BSX.

when compared with the older Promus, which is sold by Abbott under the brand name Xience, study of 1,750 patients from around the globe found the new drug-eluting Promus Element stent was comparable in results.

Conclusions were there were no measurable differences between Promus Element and Xience in regard to effectiveness and safety.

Boston Scientific was trading at $7.12, falling $0.18, or 2.47 percent, as of 12:41 PM EDT. Abbott Laboratories Inc was trading at $50.31, gaining $0.94, or 1.90 percent.

Medical Device Makers (VOLC) (EW) (XRAY) Among Hardest Hit in Japan

A large number of sectors have been hit hard in Japan, depending on the exposure they have to the country, and one not mentioned too much so far is the medical devices market, where those with the most exposure to Japan are Volcano Corp (NASDAQ:VOLC) Edwards Lifesciences Corp (NYSE:EW) and Dentsply International Inc (NASDAQ:XRAY).

About 30 percent of revenue generated by Volcano comes from Japan. Dentsply said key suppliers have been disrupted and has withdrawn its earnings guidance for 2011. Edwards Lifesciences Corp., which makes heart valves, generates about 17 percent of its revenue in Japan. At worst, Edwards sees disruptions being temporary and see no materially impact financial results from the earthquake damage.

Even so, analysts say every company should experience some degree of loss of sales as a result of the natural disaster.

Others device makers with significant exposure in Japan are Boston Scientific Corp (NYSE:BSX), with 12 percent of total sales in Japan, St Jude Medical Inc (NYSE:STJ) and Wright Medical Group Inc (NASDAQ:WMGI) at 11 percent each, Stryker Corp (NYSE:SYK) at 10 percent and Zimmer Holdings Inc (NYSE:ZMH) at 9 percent.

Larger diversified firms with less exposure are Medtronic Inc (NYSE:MDT), Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT) with from 5 percent to 6 percent of sales coming from Japan.

Of drugmakers, the largest exposure is Merck & Co Inc (NYSE:MRK) with about 8 percent of sales coming from Japan. Bristol Myers Squibb (NYSE:BMY) only has about 3 percent of sales come from there.

Volcano Corp. closed Tuesday at $23.56, down $1.21, or 4.88 percent. Edwards Lifesciences closed at $86.23, dropping $2.23, or 2.52 percent. Densply closed at $35.63, falling $1.55, or 4.17 percent.

Boston Scientific (NYSE:BSX) to Outperform in 2011

Boston Scientific (NYSE:BSX) is getting a nice boost as shares of the company are up over 6 percent after an upgrade from RBC’s analyst Glenn Novarro.

Novarro said he believes the company will outperform the overall sector in 2011, citing momentum from its new Promus Element stent and expanding margins.

Novarro wrote in a note to clients, “With shares down 5% year-to-date (significantly underperforming its med-tech peers) and sentiment low, the risk/reward is favorable. Management has set the bar low for 2011, and we see strong new product momentum and margin expansion in 2012-2015, led by the U.S. launch of Promus Element.”

What could scuttle the upgrade, according to Novarro, is if the upcoming trial for Promus Element were to fail, although he said it should come out positive.

Boston Scientific was trading at $7.60, gaining $0.44, or 6.15 percent, as of 1:37 PM EST.

Boston Scientific (NYSE:BSX) Gives Strong 2011 Guidance

Boston Scientific (NYSE:BSX) was able to exceed revenue and earnings expectations in the fourth quarter, giving the share price a boost on Tuesday, although it pulled back in after hours trading.

The company generated revenue of $2 billion in the quarter, beating analysts' estimates of $1.99 billion, although falling short of the $2.08 billion in revenue they generated last year in the same quarter.

Earnings came in at $313 million, or $0.20 a share, up from the $304 million, or $0.20 a share in the same quarter last year. Analysts had been looking for $0.10 a share.

For full year 2010, Boston Scientific had a net loss of $1.065 billion, or $0.70 a share, up from the net loss of $1.025 billion, or $0.68 a share in 2009. Revenue for the year fell from $8.19 billion to $7.81 billion year-over-year. Analysts projected annual revenue of $7.79 billion, or $0.38 a share.

For the first quarter of 2011, Boston Scientific sees GAAP earnings of $0.30 to $0.38 a share, adjusted earnings of $0.07 to $0.10 a share, and revenue reaching $1.825 billion to $1.925 billion.

For the full year 2011, the company projects GAAP earnings of $0.53 to $0.68 a share, adjusted earnings of $0.50 to $0.60 a share, and revenue of $7.5 billion to $7.9 billion.

Boston Scientific closed Tuesday at $7.13, up $0.15, or 2.15 percent.